Actuant Corp. (ATU) Tops Q3 EPS by 3c; Trims FY13 Outlook, Guides FY14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ATU Hot Sheet
Price: $21.87 --0%
Financial Fact:
Income tax expense: -25.17M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Income tax expense: -25.17M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Actuant Corp. (NYSE: ATU) reported Q3 EPS of $0.62, $0.03 better than the analyst estimate of $0.59. Revenue for the quarter came in at $344.21 million versus the consensus estimate of $343.71 million.
Actuant Corp. sees FY2013 EPS of $1.85-1.90, versus the consensus of $1.93. Actuant Corp. sees FY2013 revenue of $1.275-1.285 billion, versus the consensus of $1.29 billion.
Actuant Corp. sees FY2014 EPS of $1.95-2.05, versus the consensus of $2.15. Actuant Corp. sees FY2014 revenue of $1.315-1.340 billion, versus the consensus of $1.35 billion.
For earnings history and earnings-related data on Actuant Corp. (ATU) click here.
Actuant Corp. sees FY2013 EPS of $1.85-1.90, versus the consensus of $1.93. Actuant Corp. sees FY2013 revenue of $1.275-1.285 billion, versus the consensus of $1.29 billion.
Actuant Corp. sees FY2014 EPS of $1.95-2.05, versus the consensus of $2.15. Actuant Corp. sees FY2014 revenue of $1.315-1.340 billion, versus the consensus of $1.35 billion.
For earnings history and earnings-related data on Actuant Corp. (ATU) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Wells Fargo Names Top Pick Ahead of Q3 Earnings
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
